Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.
Michael Friedländer(Prince of Wales Hospital), Éric Pujade-Lauraine(Eau de Paris (France)), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Felix Hilpert(Krankenhaus Jerusalem), Val Gebski(The University of Sydney), Tomasz Huzarski(International Hereditary Cancer Center), Andrew R. Clamp, Vanda Salutari(Agostino Gemelli University Polyclinic), Florence Joly(Centre François Baclesse), Manuel Rodrigues(Inserm), Emma Gibbs(The University of Sydney), Kenji Tamura(Unknown), Daniel Eek(AstraZeneca (Sweden)), Ralph Bloomfield(AstraZeneca (United Kingdom)), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Richard T. Penson(Massachusetts General Hospital), Jacob Korach(Tel Aviv University), Lari Wenzel(University of California, Irvine), Maria Ornella Nicoletto, Laura Vidal(Vall d'Hebron Hospital Universitari)
Cited by 18
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k